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Abstract Patients with advanced prostate cancer often exhibit increased activation of the coagulation system. The
key activator of the coagulation cascade is the serine protease thrombin which is capable of eliciting numerous cellular
responses. We previously reported that the thrombin receptor PAR1 is overexpressed in prostate cancer. To investigate
further the role of PAR1 in prostate cancermetastasis, we examined the effects of thrombin activation on cell adhesion and
motility in PC-3 prostate cancer cells. Activation of PAR1-induced dynamic cytoskeletal reorganization and reduced PC-3
binding to collagen I, collagen IV, and laminin (P< 0.01) but not fibronectin. Expression of the cell surface integrin
receptors did not change as assessed by flowcytometry. Immunofluorescencemicroscopy revealed that PAR1 stimulation
caused reorganization of the focal adhesions, suggesting that PAR1 activation in PC-3 cells may be modulating cell
adhesion through integrin function but not expression. Furthermore, RhoAwas activated upon stimulationwith thrombin
with subsequent cell contraction, decreased cell adhesion, and induced migration towards monocyte chemoattractant
protein 1 (MCP-1; CCL2). Thus, it appears that thrombin stimulation plays a role in prostate cancer metastasis by
decreasing cell adhesion to the extracellularmatrix andpositioning the cell in a ‘‘ready state’’ formigration in response to a
chemotactic signal. Further exploration is needed to determine whether PAR1 activation affects other signaling pathways
involved in prostate cancer. J. Cell. Biochem. 101: 1292–1300, 2007.  2007 Wiley-Liss, Inc.
Key words: Rho GTPases; integrins; thrombin; monocyte chemoattractant protein 1; migration
Cytoskeletal organization is regulated by the
Ras homolog superfamily of small guanosine
triphosphatases, better knownasRhoGTPases,
which share approximately 35% sequence iden-
tity with proteins of the Ras superfamily.
The activation of Rho GTPases is necessary
for signaling between cells and extracellular
matrix (ECM) and for maintenance of cell
shape and associated focal adhesion complexes
[Burridge and Wennerberg, 2004]. To date, at
least 20 family members have been described
with Rho, Rac, and Cdc42 the best-character-
ized [Burridge and Wennerberg, 2004]. Rho is
responsible for maintaining cell shape and cell
contractionwhileRac andCdc42appear towork
together to induce cellmigration. Rac activation
induces lamellipodia and membrane ruffling
and Cdc42 produces filopodia that establish cell
polarity. Rac, but notRho, is also responsible for
forming focal complexes at the leading edges of
the lamellipodia [Ridley, 2001]. These proteins
and their associated downstream signals are
often elevated in malignant tissue [Ridley,
2004]. For example, signal transduction through
the activation of Rac and Cdc42 has been
implicated in the invasive potential of cancer
cells [Ridley, 2001].
Regulation of the Rho GTPase family occurs
through cross talks between integrins and cell
adhesion receptors, receptor tyrosine kinases,
and G protein-coupled receptors (GPCRs). In
recent years, mounting evidence supports the
role of GPCR signaling in the pathogenesis of
prostate cancer. Prostate cancer cells produce
excessive amounts of GPCR ligands such as
endothelin-1, lysophosphatidic acid, bradyki-
nin, prostaglandin, and thrombin [Offermanns
et al., 1994; Macrez et al., 1997; Gohla et al.,
1998]. They also express higher levels of GPCRs
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including the thrombin receptor (protease acti-
vated receptor 1 or PAR1) which we have
previously reported to be overexpressed in
prostate cancer cells compared to normal pros-
tate epithelium [Chay et al., 2002]. Recently, we
have demonstrated that prostate cancer cells
(e.g., PC-3 and VCaP cells) respond tomonocyte
chemoattractant protein 1 (MCP-1; CCL2)
by increasing their rate of proliferation and
migration towards CCL2 [Loberg et al., 2006].
Because PAR1 is overexpressed in metastatic
prostate cancer cells and because thrombin is
generated in excess in patients with advanced
prostate cancer [Lind et al., 2003], we investi-
gated the link between thrombin and prostate
cancer cellmigration by examining the effects of
PAR1 activation on adhesion, migration, and
Rho GTPase expression in prostate cancer cells
and have demonstrated that stimulation of
PAR1 induces a migratory phenotype that
promotes prostate cancer cell migration in
response to the chemotactic signal of CCL2.
MATERIALS AND METHODS
Cell Culture
PC-3 human prostate cancer cell line (ATCC,
Manassas, VA) was cultured in RPMI-1640
supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin/ampho-
tericin B (Invitrogen Corp., Carlsbad, CA) at
378C in a humidified incubator with 5% CO2.
Cells were passaged by trypsinization and were
detached for use in all assays by exposure for 1 h
to 0.5mMEDTA inHank’s balance salt solution
(HBSS). Stock solutions of 1 mM thrombin
(Sigma-Aldrich, St. Louis,MO) and 6mMTRAP
(Bachem, King of Prussia, PA) were prepared in
sterile distilled water and stored at208C until
use. Cells were serum-starved for 2 h in RPMI-
1640 prior to PAR1 activation. PAR1 activation
was performed in serum-free RPMI-1640.
Adhesion Assay
Adhesion assay was performed as previously
described [Tantivejkul et al., 2003]. Briefly,
wells of 96-well flat bottom tissue culture plates
were coated overnight at 48C with 100 mL of
collagen I, collagen IV, fibronectin, laminin, or
vitronectin (10 mg/ml in phosphate buffered
saline (PBS)) (BD Biosciences, San Jose, CA).
After serum starvation and EDTA-release, PC-
3 cells were treated for 30 min with 2 or 10 nM
thrombin or 100 mM TRAP6 in RPMI-1640
containing 0.1% BSA at 378C with agitation.
Wells coated with proteins were blocked with
0.1%BSA inRPMI-1640at 378C for 30minprior
to the addition of 100 mL of 2 105 cells/ml to
each well. After 30 min in an incubator, for
experiments to plot ECM protein adhesion
profiles wells were washed three times with
PBS to remove unattached cells. Adherent cells
were then fixed for 15 min with 4% formalde-
hyde in PBS and stained for 5 min with 0.5%
crystal violet in 20%methanol. Acetic acid (30%
v/v) was used to dissolve the crystal violet, and
the optical densitywas determined at 595nmon
a VersaMax Microtiter plate reader (Molecular
Devices, Sunnyvale, CA). In experiments to
investigate changes in ECM protein adhesion
after PAR1 activation, cells were first stained
with 5 mM calcein AM (Molecular Probes, Inc.,
Eugene, OR) for 30 min before seeding onto
protein-coated wells. After 30 min incubation,
wells were washed three times with PBS to
remove unattached cells. Absorbance was mea-
sured at 490 nmexcitation and 530 nmemission
wavelengths. Experiments were performed in
triplicate and repeated twice.
Flow Cytometry
Serum-starved PC-3 cells were treated with
10 nM thrombin in serum-free RPMI-1640
containing 1% antibiotic/antimycotic for 12 h
before EDTA-release. Cell concentrations were
adjusted to 1 106 cells/ml and incubated for 1h
with anti-a1, anti-a2, anti-a3, anti-a5, anti-a6,
anti-b1, anti-b4, anti-avb3 or anti-avb5 mouse
IgGs (Chemicon International, Inc., Temecula,
CA) at 48C. Cells were washed twice in PBS,
incubated for 30 min with fluorescein-conju-
gated secondary antibodies (Molecular Probes,
Inc.) at 48C and fixed with 4% formaldehyde in
PBS prior to flow cytometry analysis using a
FACScan flow cytometer (BD Biosciences, Palo
Alto, CA). Experiments were performed in
triplicate and repeated twice.
Immunofluorescence
For actin cytoskeleton visualization, 1 105
PC-3 cells in culture media were plated onto
chambered glass slides and incubated over-
night. After serum starvation, cells were trea-
tedwith 2 or 10 nM thrombin, or 100 mMTRAP6
for an additional 2 h to activate PAR1. Cells
werewashed twicewith PBS, fixed for 10min in
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4% formaldehyde, permeabilized for 5 min with
0.1% Triton X-100, and blocked for 20 min with
1% BSA prior to staining with AlexaFluor568-
conjugated phalloidin (Molecular Probes, Inc.),
anti-b1 integrin (BD Biosciences), or FITC-
conjugated anti-phosphotyrosine (Upstate Bio-
technology, Lake Placid, NY). Coverslips were
mounted with Prolong anti-fade mounting
media (Molecular Probes, Inc.) after slides were
washed twice with PBS. Analysis was perform-
ed on an Olympus FluoView 500 Laser Scan-
ning Confocal Microscope (Olympus, Melville,
NY) through TheUniversity ofMichiganMicro-
scopic Imaging Laboratory.
Rho/Rac/Cdc42 Activity Assay
Rhotekin and PAK binding assays were
performed as previously described [Sander
et al., 1998]. Briefly,Escherichia coliBL21 cells
transformedwith the glutathione S-transferase
(GST)-PAK-CD (PAK-CRIB domain) construct
or GST-Rhotekin Rho binding domain (GST-
RBD) construct (gifts from John Collard of
Netherlands Cancer Institute) were grown at
378C overnight. Expression of recombinant
protein was induced with 100 mM isopropylthio-
galactoside for 2 h. Cells were pelleted and
resuspended in lysis buffer (50 mM Tris-HCl,
pH 8.0, 2 mM MgCl2, 200 mM Na2S2O, 10%
glycerol, 20% sucrose, 2 mM dithiothreitol,
1 mM benzamide, 1 mM PMSF, 1 mg/ml leupep-
tin, 1 mg/ml pepstatin, and 1 mg/ml aprotinin).
After sonication, cell lysateswere centrifugedat
48C for 20 min at 45,000g and supernatant was
incubated with glutathione-coupled sepharose
4B beads (AmershamBiosciences Corp., Piscat-
away, NJ) for 30 min at 48C. Protein bound
beads were washed three times in lysis buffer
and resuspended in GST-FISH buffer (50 mM
Tris, pH 7.4, 2 mM MgCl2, 100 mM NaCl, 10%
glycerol, 1% NP-40, 1 mM benzamide, 1 mM
PMSF 1 mg/ml leupeptin, 1 mg/ml pepstatin, and
1 mg/ml aprotinin). PC-3 cells were starved for
2 h, stimulated with 10 nM thrombin, washed
three times with ice-cold PBS, and lysed in
GST-FISH buffer. Protein concentration in the
supernatant was determined by Biorad pro-
tein determination dye (Bio-Rad Laboratories,
Hercules, CA). Supernatant (1 mg) was incu-
bated with glutathione-sepharose GST-fusion
protein beads for 30 min at 48C. Pull-down
beads were washed three times in GST-FISH
buffer, resuspended in Laemmli buffer and
analyzed by Western blotting using anti-RhoA
(Cytoskeleton, Inc., Denver, CO), anti-Rac1
(Upstate USA, Charlottesville, VA), and anti-
Cdc42 (BD Biosciences) monoclonal antibodies.
Bands were visualized by ECL chemilumines-
cence (Promega Corp., Madison, WI) and auto-
radiographic intensitieswere quantitatedusing
Image J software (NCI, Bethesda, MD).
In Vitro Wound Assay
Wells of 24-well tissue culture plates were
coatedwith collagen I, collagen IV, laminin, and
fibronectin (10 mg/ml) as described earlier. PC-3
cells (1 105) were seeded perwell and grown to
confluence. A denuded wound area wasmade in
each well with a standard 20–200 mL pipet tip,
and wells were washed three times to remove
any floating cells. Wounds were visualized
through a Nikon Diaphot 200 microscope at
10 magnification, and images were recorded
with a Nikon CoolPix990 digital camera to
confirm that they were completely free of cells.
Cells were treated with 2 or 10 nM thrombin or
100 mMTRAP6 for 24 h at 378C in a cell culture
incubator. Wounded areas were reimaged, and
the number of cells migrated into the denuded
area was counted. Experiments were perform-
ed in triplicate and repeated three times.
Migration Assay
Increasing concentrations of CCL2 (1–100 ng/ml)
or conditioned media was added to the lower
chamber of a 24well plate. Cells were harvested
byEDTArelease and resuspended in serum free
media at 5 104 cells/ml. Cells (2.5 104) were
added to the upper chamber of the transwell
insert and incubated for 24 h at 378C and 5%
CO2 atmosphere. At the end of the incubation
period, the cells were fixed with 4% formalde-
hyde in PBS for 5 min. Non-adherent cells were
removed from inside the inserts with cotton-
tipped swab. Cells which had migrated to the
underside of the insert were stained with 0.5%
crystal violet for 5 min and rinsed thoroughly
with tap water. Inserts were allowed to dry and
the cells were counted using an inverted micro-
scope.
Statistical Analysis
Results were expressed as mean standard
deviation of triplicates. Statistical analysis was
performed using the two-tailed Student’s t-test.
A P-value of less than 0.05 or better was
considered significant.
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RESULTS
PAR1 Stimulation Decreases
Cell Adhesion to ECM
To investigate the effects of PAR1 activation
on prostate cancer cell adhesion to proteins of
the ECM, we first determined the cell adhesion
potential of PC-3 cells on collagen I, collagen IV,
fibronectin, laminin, and vitronectin. PC-3 cells
preferentially adhered to collagen more than
laminin, fibronectin, and vitronectin (Fig. 1A).
At 0.1mg/ml protein coating concentration,PC-3
cells bound to collagens I and IV 2- to 3-fold
higher than laminin, fibronectin, or vitronectin.
Cells adhered minimally to vitronectin even at
high protein concentrations. Upon PAR1 acti-
vation by thrombin or TRAP6, PC-3 cell adhe-
sion to collagen I, collagen IV, and laminin
modestly but significantly decreased (*P< 0.01,
Fig. 1B).
Since integrins are responsible for cell-ECM
adhesion, we then examined the integrin
expression profile of PC-3 cells. Analysis of cell
surface expression of integrin subunits by flow
cytometry showed that PC-3 cells had the
highest overall expression of the b1 integrin
subunit (Fig. 2). The collagen-binding integrin
subunits a2 and a3 were more abundant than
the laminin-binding integrin subunits a1, a6,
and b4 and the fibronectin-binding integrin
subunit a5. The vitronectin receptors avb3 and
avb5 integrins were the least detected. Thus,
the expressions of cell surface integrins sup-
ported the PC-3 cell adhesion profile shown in
Figure 1A. However, PAR1 stimulation of cells
did not affect expression of surface integrins
(Fig. 2).
PAR1 Stimulation Causes Retraction
of the Actin Cytoskeleton
To determine whether PAR1 activation influ-
enced actin reorganization, PC-3 cells were
immunostained with fluorescence conjugated-
phalloidin (Fig. 3A,E,I,M). Treatment of PC-3
cells with thrombin or TRAP6 caused retraction
of the actin cytoskeleton, and cells demon-
strated numerous microspike extensions from
the cell body. PAR1 activation with 10 nM
thrombin induced a more pronounced presence
of microspikes than with 2 nM thrombin.
Furthermore, unstimulated PC-3 cells appear-
ed more flattened compared to PAR1-activated
Fig. 1. PAR1 activation influences PC-3 adhesion. A: Using a
range of ECM protein concentrations, adhesion profiles were
generated for untreated PC-3 cells. The highest binding affinity
was to collagen I and collagen IV as indicated by higher optical
density at 595 nm after crystal violet staining at lower protein
concentrations (X axis) compared to laminin, fibronectin and
vitronectin. B: PAR1 activation significantly decreased cell
adhesion to collagen I (Col I, 0.1 mg/ml), collagen IV (Col IV,
0.1 mg/ml) and laminin (LN, 1 mg/ml) (*P<0.01), but not
fibronectin (FN, 10 mg/ml). Protein concentrations in the sub-
saturated linear range of adhesion as determined in (A)were used
to coat wells. Fluorescence intensity unit (Y axis) represents the
mean intensity at 490 nm excitation/530 nm emission after
calcein AM staining. Statistical significance is indicated by an
asterisks (*) with P<0.01 and compares individual PAR1
thrombin (Thr) or TRAP6 stimulated samples to control untreated
samples.
Fig. 2. Expression of cell surface integrins are unaffected by
PAR1 activation. Flow cytometry analysis of cell surface integrin
expression was performed to compare untreated control, 10 nM
thrombin (Thr)-, and 100 mM TRAP6 (TRAP)-stimulated PC-3
cells. Relative expression (Y axis) represents the mean fluores-
cence intensity for each sample. Data points represent mean
standard deviation (n¼3).
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cells, suggesting that PAR1 activation caused
cell rounding. Since focal adhesion proteins are
generally activated by tyrosine phosphoryla-
tion, we used anti-b1 integrin (Fig. 3B,F,J,N),
and anti-phosphotryosine 4G10 (Fig. 3C,G,K,O)
monoclonal antibodies to determine whether
PAR1 activation contributed to changes in focal
adhesion organization. In untreated control
cells actin, b1 integrins, and phosphotyrosine
colocalized at the broad edges of the cells at the
focal adhesions (Fig. 3A–D, arrowheads). Sti-
mulation with thrombin or TRAP6 caused
changes in b1 integrin and phosphotyrosine
distribution within the cells (Fig. 3E–P). Stron-
ger signals were observed around the peri-
nuclear regions within the actin contractile
ring. Colocalization was observed within the
protruding microspikes, but not on the cell
edges (arrows).
Rho GTPases Are Activated in
Response to PAR1 Stimulation
As changes in actin cytoskeletal organization
are regulated by Rho GTPases, we measured
the activities of RhoA, Rac, and Cdc42 in
response to PAR1 stimulation. Using a GST-
RBD fusion protein pull-downassay,we demon-
strated that RhoAwas rapidly activated (RhoA-
GTP) within 1 min of PAR1 stimulation with
10 nM thrombin and remained activated by
approximately twofold for at least 1 h (Fig. 4).
Similarly, thrombin treatment-induced Cdc42
activation (Cdc42-GTP) within 5 min, but
declined to basal level by 30 min as shown by
using a GTP-PAK fusion protein pull-down
assay. However, there was no change in the
level of Rac activation. Similar activation
profiles were observed when cells were treated
Fig. 3. PAR1 activation induces changes in cell morphology.
PC-3 cells grown overnight on collagen I-coated glass coverslips
were treated with thrombin for 2 h in serum-free RPMI-1640
followed by staining with AlexaFluor568-conjugated phalloidin
(for actin), mouse monoclonal anti-b1 integrin antibody/CY5-
conjugated goat anti-mouse secondary, or FITC-conjugated anti-
phosphotyrosine (pY) antibody prior to confocal microscopy.
Representative images of control untreated cells (A–D), 2 nM
thrombin-treatedcells (E–H), 10nMthrombin-treated cells (I–L),
and 100 mM TRAP6-treated cells (M–P) were captured at 60
magnification. Images of Actin (red), Cy5-labeled b1 integrin
(pseudocolored blue), and phosphotryosine (green) were over-
layed to facilitate visualization of colocalization (D,H,L,P).
Arrowheads represent focal adhesions and arrows indicate
microspikes and areas of colocalization.
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To investigate the role of PAR1 activation on
cell movement, we utilized the wounded mono-
layer assay to assess PC-3 cell motility on ECM
component proteins. PAR1activationwith 2nM
thrombin significantly decreased cell migration
on plastic, collagen I, collagen IV, and laminin
(P< 0.05, Fig. 5A,B). There was also a trend
toward decreased mobility with 10 nM throm-
bin and 100 mMTRAP6 treatments, although to
a lesser extent than with the lower thrombin
concentration. Cell motility on fibronectin was
not affected.
PAR1 Stimulation Enhances PC-3
Chemotactic Migration to CCL2
To investigate the role of PAR1 stimulation
on migration in response to CCL2, a known
chemoattractant [Loberg et al., 2006], PC-3 cells
were treated with 100 mM TRAP6 for 24 h prior
to the migration experiments. Stimulation of
PAR1 resulted in a significant increase in
migration towards CCL2 (100 ng/ml) compared
to unstimulated cells (P< 0.01, Fig. 6).
DISCUSSION
We have previously shown that bone-derived
prostate cancer cells overexpress functional
PAR1 receptor compared to soft tissue-derived
prostate cancer cells and normal prostate
epithelial cells [Chayet al., 2002]. In this article,
we begin to investigate the effects of PAR1
activation on the metastatic properties of
prostate cancer cells. PAR1 activation occurs
through thrombin cleavage at the receptor
extracellular amino terminus, therebyunmask-
ing a new tethered ligand which serves as an
intramolecular activator [Coughlin, 1999].
Hence, this activation is irreversible, and
PAR1 signaling can therefore only be termi-
nated by intracellular receptor recycling and
degradation. As PC-3 cells express both PAR1
and PAR4 (data not shown), stimulation with
thrombin activates both intracellular signaling
pathways. Therefore, we also utilized the
synthetic activator TRAP6 which encodes the
cleaved amino-terminus of the PAR1 receptor
and exclusively targets PAR1. Activation with
thrombin was performed at 2 and 10 nM
concentrations, equivalent to physiological and
pharmaceutical levels, respectively [Huang
et al., 2000]. Activation with 100 mM TRAP6
was chosen as this concentration mimics cal-
cium release with 10 nM thrombin [Darmoul
et al., 2003].
Cells interact with the microenvironment
through the cell surface integrins receptor
which mediates cell adhesion to the ECM.
Signal transduction through the integrins has
been shown to play a role in prostate cancer
metastasis [Tantivejkul et al., 2004]. We
demonstrated that cell adhesion to collagens I
and IV and laminin was decreased by PAR1
activation. In addition, we showed that the
expression of cell surface integrins correlated
with PC-3 cell adhesion profiles and was con-
sistent with previous findings for these cells
[Haywood-Reid et al., 1997]. Since PC-3 cells
were derived from a prostate cancer bone
metastasis, it is not surprising that these cells
expressed the highest levels of integrin sub-
units associated with collagen binding (e.g., a2,
a3, and b1). Adhesion to fibronectin was not
affected by PAR1 activationmost likely because
Fig. 4. Rho/Rac/Cdc42 activity in PAR1-stimulated PC-3 cells.
Cell lysates collected at 0, 1, 5, 10, 30, and 60 min after
stimulation with 10 nM thrombin were used to perform Rho
GTPase pull-down assays. Total amount of each protein was
determined from 20 mg of total cell lysates. Fold-change in
activation was calculated by analyzing the band intensity and
adjusted as a ratio to untreated control.
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fibronectin integrin receptor a5 subunit was
expressed at a lower level compared to collagen
and laminin receptors. Similarly, vitronectin
receptors (avb3 and avb5) were the least
expressed on PC-3 cells, probably accounting
for the insignificant adhesion of PC-3 cells to
vitronectin compared to other proteins in this
study.
Despite detecting decreased adhesion of
PAR1-activated prostate cancer cells to ECM
components, we did not identify concomitant
changes in cell surface expression of integrin
receptors suggesting that PAR1 activation may
modulate integrin function and organization
through other mechanisms. The engagement
of the integrins to ECM proteins activates a
variety of intracellular signaling through the
protein tyrosine kinases associated with the
focal adhesion complex, such as focal adhesion
kinase, paxillin, p130Cas, and phosphatidylino-
sitol 3-kinase [Giancotti and Ruoslahti, 1999].
Activation of the focal adhesion through tyr-
osine phosphorylation is necessary to provide
traction for migration on ECM proteins. We
investigated changes in focal adhesion organi-
zation by immunofluorescence staining of actin
Fig. 5. PAR1 activation by thrombin reduced random cell motility. Wound assay was performed on cells
cultured to 80–100% confluency on untreated (Plastic), collagen I- (Col I), collagen IV- (Col IV), laminin-
(LN), and fibronectin-coated (FN) tissue culture plates. A: The images represent the wounded areas at 0 and
24 h of incubationwith orwithout thrombin.B: Quantification of the cells that havemigrated into thewound
demonstrated that treatmentwith 2nM thrombin significantly decreased cellmigrationonplastic, collagen I,
collagen IV, and laminin (*P<0.05).
1298 Loberg et al.
stress fibers, b1 integrin subunits, and tyrosine-
phosphorylated proteins. Our results showed
that upon activation with thrombin, colocaliza-
tion of actin, b1 integrin, and tyrosine-phos-
phorylated protein was lost, suggesting a
disruption of focal adhesions consistent with
our observations of rounding up in treated cells.
Activation of RhoA is essential for focal
adhesion assembly in response to cell stimula-
tion [Ridley and Hall, 1992]. The GPCR PAR1
has been shown to activate RhoA throughGa12/
13 and p115Rho-GEF thereby dynamically
regulating actin cytoskeleton and focal adhe-
sions [Whitehead et al., 2001]. PAR1-activated
RhoA has been shown to induce cell rounding
and neurite retraction in neuronal cells [Jalink
et al., 1994]. In addition, thrombin-treated
endothelial cells show cell contraction leading
to endothelial cell barrier dysfunction [van
Nieuw Amerongen et al., 2000]. Recently, it
has been reported that PAR1 activation is
mediated by LARG (leukemia-associated Rho-
GEF) in PC-3 cells and that transfection with
LARG siRNA nearly abolishes thrombin-
induced PC-3 cell rounding response [Wang
et al., 2004]. Furthermore, the cooperation of
Rho, Rac, and Cdc42 is required to regulate cell
motility. Activation of Cdc42 induces the for-
mation of filopodia which establishes cell polar-
ity by sensing chemotactic signals [Arthur and
Burridge, 2001]. Rac coordinates focal adhesion
assembly in the lamellipodium and causes
membrane ruffling at the leading edge [Nobes
and Hall, 1995]. Activated Rho then generates
contractile forces that push a cell body toward
the leading edge and initiate actin polymeriza-
tion [Ridley, 2001].Wedemonstrated thatRhoA
is activated byPAR1 stimulationwith thrombin
which induced cell contraction. In addition,
Cdc42 was also initially activated and declined
rapidly to basal level. Due to the fact that Cdc42
is known to regulate the formation of filopodia,
it is not surprising that thrombin-stimulated
cells have numerous microspikes along the cell
periphery. Rac, however, was not affected by
thrombin treatment. We have also demon-
strated that random cell motility was reduced
when cells were stimulated with thrombin but
migration towards a known chemoattractant,
CCL2, was enhanced.
Activation of PAR1 has been shown to
increase the metastatic potential of many
other types of cancer [Nierodzik et al., 1992;
Henrikson et al., 1999; Darmoul et al., 2003].
Overexpression of PAR1 in metastatic prostate
cancer suggests that it may be involved in
disease progression. It has also been shown
that PAR1 activation of RhoA in LNCaP cells
was enhanced by dihydrotestosterone, empha-
sizing the importance of PAR1 signaling path-
way in prostate cancer [Greenberg et al., 2003].
In this study, we have examined the role of
PAR1 activation in the modulation of cell ad-
hesion, motility, and actin organization. Our
results suggest that PAR1 activation in PC-3
alters cell structure, causes a decrease in cell
adhesion, and enhances migration. Recently,
we reported that CCL2 is highly expressed and
secreted by bone marrow endothelial (BME)
cells and demonstrated that CCL2 from BME
cells served as a potent chemoattractant of
prostate cancer cells in vitro [Loberg et al.,
2006]. These data point out the importance of
differentiation betweenmeasuringmotility and
migration. In these experiments, PAR1 stimu-
lation induced changes in cell structure that
enhanced themigratory abilities of the prostate
cancer cells, an important step in metastasis.
These results suggest an interesting paradigm
of bone-related events in prostate cancer such
that upregulation of PAR1 andCCR2 (theCCL2
Fig. 6. PAR1 activation by thrombin enhances migration
towards CCL2. Increasing concentrations of CCL2 (1–100 ng/
ml) or conditioned media was added to the lower chamber of a
24-well plate. Cells were harvested and resuspended in serum
freemedia at 5 104 cells/ml. Cells (2.5104)were added to the
upper chamber of the transwell insert and incubated for 24 h at
378C and 5% CO2 atmosphere. At the end of the incubation
period, the cells were fixed with 4% formaldehyde in PBS for
5 min and non-adherent cells were removed. Cells which had
migrated to the underside of the insert were stained with 0.5%
crystal violet and counted using an inverted microscope.
Stimulationof PAR1 resulted in a significant increase inmigration
towards CCL2 (100 ng/ml) compared to unstimulated cells
(P<0.01).
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high affinity receptor) on prostate cancer cells
‘‘primes’’ these cells to metastasize to sites of
elevated CCL2 expression, that is, the bone
microenvironment. These data, as well as the
data of others, suggest that the presence of
increased thrombin in cancer patients may
contribute to tumorigenesis and metastasis.
Further work is necessary to establish a link
between PAR1, CCL2 expression, and prostate
cancer bone metastasis.
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